Skip to main content

Site notifications

Notice for ivosidenib (Servier Laboratories Australia Pty Ltd)

Active ingredients
ivosidenib
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Film-coated tablet
Indication
TIBSOVO monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation, who were previously treated by at least one prior line of systemic therapy
Therapeutic area
Oncology

Help us improve the Therapeutic Goods Administration site